PTC Therapeutics (PTCT)
(Delayed Data from NSDQ)
$51.36 USD
+0.25 (0.49%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $51.38 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth F Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PTCT 51.36 +0.25(0.49%)
Will PTCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PTCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTCT
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
PTC Therapeutics (PTCT) Surges 11.2%: Is This an Indication of Further Gains?
PTCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength?
All You Need to Know About PTC Therapeutics (PTCT) Rating Upgrade to Buy
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy?
Other News for PTCT
PTC Therapeutics Earnings Preview
PTC Therapeutics Q2 2025 Earnings Preview
SA analyst upgrades/downgrades: AMD, TSLA, SHEL, PTCT
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
PTC Therapeutics: Uncertainty Abounds Ahead Of Q2 Earnings - I'm Upgrading To 'Hold'